These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35041914)

  • 1. Design and molecular insights of drug-active metabolite based co-amorphous formulation: A case study of toltrazuril-ponazuril co-amorphous.
    Li B; Wang Y; Feng Y; Yuan D; Xu R; Jiang C; Xiao X; Lu S
    Int J Pharm; 2022 Mar; 615():121475. PubMed ID: 35041914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tannic acid as a co-former in co-amorphous systems: Enhancing their physical stability, solubility and dissolution behavior.
    Fael H; Demirel AL
    Int J Pharm; 2020 May; 581():119284. PubMed ID: 32243965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Felodipine-indomethacin" co-amorphous supersaturating drug delivery systems: "Spring-parachute" process, stability, in vivo bioavailability, and underlying molecular mechanisms.
    Li YW; Zhang HM; Cui BJ; Hao CY; Zhu HY; Guan J; Wang D; Jin Y; Feng B; Cai JH; Qi XR; Shi NQ
    Eur J Pharm Biopharm; 2021 Sep; 166():111-125. PubMed ID: 34119671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Considerations for the selection of co-formers in the preparation of co-amorphous formulations.
    Yarlagadda DL; Sai Krishna Anand V; Nair AR; Navya Sree KS; Dengale SJ; Bhat K
    Int J Pharm; 2021 Jun; 602():120649. PubMed ID: 33915186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs.
    Baghel S; Cathcart H; O'Reilly NJ
    J Pharm Sci; 2016 Sep; 105(9):2527-2544. PubMed ID: 26886314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gelation Elimination and Crystallization Inhibition by Co-Amorphous Strategy for Amorphous Curcumin.
    Han J; Wei Y; Li L; Song Y; Pang Z; Qian S; Zhang J; Gao Y; Heng W
    J Pharm Sci; 2023 Jan; 112(1):182-194. PubMed ID: 35901945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tranilast-matrine co-amorphous system: Strong intermolecular interactions, improved solubility, and physiochemical stability.
    Hu D; Chen X; Li D; Zhang H; Duan Y; Huang Y
    Int J Pharm; 2023 Mar; 635():122707. PubMed ID: 36764418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hot melt extrusion technology for improved dissolution, solubility and "spring-parachute" processes of amorphous self-micellizing solid dispersions containing BCS II drugs indomethacin and fenofibrate: Profiles and mechanisms.
    Shi NQ; Wang SR; Zhang Y; Huo JS; Wang LN; Cai JH; Li ZQ; Xiang B; Qi XR
    Eur J Pharm Sci; 2019 Mar; 130():78-90. PubMed ID: 30684657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indomethacin co-amorphous drug-drug systems with improved solubility, supersaturation, dissolution rate and physical stability.
    Fael H; Demirel AL
    Int J Pharm; 2021 May; 600():120448. PubMed ID: 33675920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism-based selection of stabilization strategy for amorphous formulations: Insights into crystallization pathways.
    Edueng K; Mahlin D; Larsson P; Bergström CAS
    J Control Release; 2017 Jun; 256():193-202. PubMed ID: 28412224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
    Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
    J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-Amorphous Solid Dispersions for Solubility and Absorption Improvement of Drugs: Composition, Preparation, Characterization and Formulations for Oral Delivery.
    Karagianni A; Kachrimanis K; Nikolakakis I
    Pharmaceutics; 2018 Jul; 10(3):. PubMed ID: 30029516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
    Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of polymer addition on the non-strongly interacting binary co-amorphous system carvedilol-tryptophan.
    Wang Y; Grohganz H; Rades T
    Int J Pharm; 2022 Apr; 617():121625. PubMed ID: 35259442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into co-amorphous systems in therapeutic drug delivery.
    Singh R; Joshi V; Mehetre N; Sangamwar AT
    Ther Deliv; 2021 Mar; 12(3):245-265. PubMed ID: 33745286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the physical stability of three nimesulide-indomethacin co-amorphous systems from the perspective of molecular aggregates.
    Wang M; Liu S; Jia L; Zhang J; Du S; Gong J
    Eur J Pharm Sci; 2020 Apr; 147():105294. PubMed ID: 32147483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microfibrous Solid Dispersions of Poorly Water-Soluble Drugs Produced via Centrifugal Spinning: Unexpected Dissolution Behavior on Recrystallization.
    Marano S; Barker SA; Raimi-Abraham BT; Missaghi S; Rajabi-Siahboomi A; Aliev AE; Craig DQM
    Mol Pharm; 2017 May; 14(5):1666-1680. PubMed ID: 28296409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refining stability and dissolution rate of amorphous drug formulations.
    Grohganz H; Priemel PA; Löbmann K; Nielsen LH; Laitinen R; Mullertz A; Van den Mooter G; Rades T
    Expert Opin Drug Deliv; 2014 Jun; 11(6):977-89. PubMed ID: 24754747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Permeability of glibenclamide through a PAMPA membrane: The effect of co-amorphization.
    Ruponen M; Visti M; Ojarinta R; Laitinen R
    Eur J Pharm Biopharm; 2018 Aug; 129():247-256. PubMed ID: 29894814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-Amorphous Screening for the Solubility Enhancement of Poorly Water-Soluble Mirabegron and Investigation of Their Intermolecular Interactions and Dissolution Behaviors.
    An JH; Lim C; Kiyonga AN; Chung IH; Lee IK; Mo K; Park M; Youn W; Choi WR; Suh YG; Jung K
    Pharmaceutics; 2018 Sep; 10(3):. PubMed ID: 30189645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.